## **Baillie Gifford**

Baillie Gifford European Growth Trust plc Vote Disclosure\* Q1: 1 January 2024 – 31 March 2024

\*This voting report reflects the votes cast by Baillie Gifford during the quarter on behalf of the investment trust. No verification is undertaken as to whether all such votes have been accepted.

\*\* AGM = Annual General Meeting; EGM = Extraordinary General Meeting; SGM = Special General Meeting; CRT = Court Meeting; OTH = Other Meeting; CLS = Class Meeting

Company	Meeting Type	Meeting Date	Resolution	Proposal	Proposal Type	Vote	Reason
DSV	AGM	14/03/2024	2	Annual Report	Management	Cast For	
DSV	AGM	14/03/2024	3	Allocation of Income	Management	For	
DSV	AGM	14/03/2024	4	Non-Executive	Management	For	
	,	, 00, 202 .	•	Remuneration	aagoo		
DSV	AGM	14/03/2024	5	Remuneration	Management	For	
DSV	AGM	14/03/2024	6.01	Elect Director(s)	Management	For	
DSV	AGM	14/03/2024	6.02	Elect Director(s)	Management	For	
DSV	AGM	14/03/2024	6.03	Elect Director(s)	Management	For	
DSV	AGM	14/03/2024	6.04	Elect Director(s)	Management	For	
DSV	AGM	14/03/2024	6.05	Elect Director(s)	Management	For	
DSV	AGM	14/03/2024	6.06	Elect Director(s)	Management	For	
DSV	AGM	14/03/2024	6.07	Elect Director(s)	Management	For	
DSV	AGM	14/03/2024	6.08	Elect Director(s)	Management	For	
DSV	AGM	14/03/2024	7.01	Appoint/Pay Auditors	Management	For	
DSV	AGM	14/03/2024	8.1	Articles of Association	Management	For	
DSV	AGM	14/03/2024	8.2	Share Repurchase	Management	For	
DSV	AGM	14/03/2024	8.3.A	Director Related	Management	For	
DSV	AGM	14/03/2024	8.3.B	Articles of Association	Management	For	
DSV	AGM	14/03/2024	8.4	Shareholder Resolution - Social	Shareholder	For	We supported the shareholder resolution asking for a report on DSV's efforts and risks related to human and labour rights, as we believe that additional transparency would be beneficial for stakeholders. Our decision also aligns with management recommendation.
Sartorius Stedim Biotech	n MIX	26/03/2024	1	Annual Report	Management	For	
Sartorius Stedim Biotech		26/03/2024	2	Annual Report	Management	For	
Sartorius Stedim Biotech	n MIX	26/03/2024	3	Allocation of Income	Management	For	
Sartorius Stedim Biotech	n MIX	26/03/2024	4	Non-Executive Remuneration	Management	For	
Sartorius Stedim Biotech	n MIX	26/03/2024	5	Remuneration	Management	Against	We opposed the remuneration report because the aggregate fees paid to the board of directors in 2023 exceeded the maximum amount approved by shareholders at the 2023 AGM, which we consider to be poor governance.
Sartorius Stedim Biotech		26/03/2024	6	Remuneration	Management	For	
Sartorius Stedim Biotech	n MIX	26/03/2024	7	Remuneration	Management	For	

Sartorius Stedim Biotech	MIX	26/03/2024	8	Non-Executive	Management	For	
Cartoriae Cteamin Bioteen		20,00,202	Ü	Remuneration	Managomoni	. 0.	
Sartorius Stedim Biotech	MIX	26/03/2024	9	Remuneration	Management	For	
Sartorius Stedim Biotech	MIX	26/03/2024	10	Non-Executive	Management	For	
				Remuneration			
Sartorius Stedim Biotech	MIX	26/03/2024	11	Remuneration	Management	For	
Sartorius Stedim Biotech	MIX	26/03/2024	12	Elect Director(s)	Management	For	
Sartorius Stedim Biotech	MIX	26/03/2024	13	Elect Director(s)	Management	For	
Sartorius Stedim Biotech	MIX	26/03/2024	14	Appoint/Pay Auditors	Management	For	
Sartorius Stedim Biotech	MIX	26/03/2024	15	Appoint/Pay Auditors	Management	For	
Sartorius Stedim Biotech	MIX	26/03/2024	16	Share Repurchase	Management	For	
Sartorius Stedim Biotech	MIX	26/03/2024	17	Articles of Association	Management	For	
Sartorius Stedim Biotech	MIX	26/03/2024	18	Amendment of Share	Management	For	
				Capital			
Sartorius Stedim Biotech	MIX	26/03/2024	19	Amendment of Share	Management	Against	We opposed the resolution which sought
				Capital			authority to issue equity because the
							potential dilution levels are not in the
0 1 2 0 1 5	B 4157	00/00/0004	00	A 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			interests of shareholders.
Sartorius Stedim Biotech	MIX	26/03/2024	20	Amendment of Share	Management	Against	We opposed the resolution which sought
				Capital			authority to issue equity because the potential dilution levels are not in the
							interests of shareholders.
Sartorius Stedim Biotech	MIX	26/03/2024	21	Amendment of Share	Management	Against	We opposed the resolution which sought
Sartonus Stealin Biotech	IVIIX	20/03/2024	21	Capital	Management	Against	authority to issue equity because the
				Capital			potential dilution levels are not in the
							interests of shareholders.
Sartorius Stedim Biotech	MIX	26/03/2024	22	Amendment of Share	Management	For	
				Capital			
Sartorius Stedim Biotech	MIX	26/03/2024	23	Amendment of Share	Management	For	
				Capital			
Sartorius Stedim Biotech	MIX	26/03/2024	24	Employee Equity Plan	Management	For	
Sartorius Stedim Biotech	MIX	26/03/2024	25	Employee Equity Plan	Management	For	
Sartorius Stedim Biotech	MIX	26/03/2024	26	Amendment of Share	Management	For	
				Capital			